Outcomes assessed included objective response rate (ORR), immune markers (CD4–CD8 ratio and natural killer (NK) cells), tumor markers (CA125, carcinoembryonic antigen (CEA), and CYFRA21-1), and adverse events. The gene discussed is CD8A; the disease is neoplasm.